PCM
PBYI icon

Penserra Capital Management’s Puma Biotechnology PBYI Stock Holding History

Penserra Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-930
Closed -$6K – 1499
2021
Q3 		$6K Buy
930
+10
+1% +$75 ﹤0.01% 1402
2021
Q2 		$8K Buy
920
+15
+2% +$152 ﹤0.01% 1288
2021
Q1 		$8K Sell
905
-10
-1% -$112 ﹤0.01% 1058
2020
Q4 		$9K Buy
915
+577
+171% +$5.84K ﹤0.01% 935
2020
Q3 		$3K Buy
+338
New +$3.44K ﹤0.01% 887

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Penserra Capital Management's PBYI Position: Q4 2021 in Review

Penserra Capital Management sold out of Puma Biotechnology (PBYI) in Q4 2021, closing a stake of 930 shares — an estimated $6K sold.

Penserra Capital Management first reported a position in PBYI in Q3 2020 and held it in 5 quarters. The position peaked at $9K in Q4 2020. 102 funds tracked by Wall St. Rank hold PBYI as of Q4 2021.

  • Penserra Capital Management reported no remaining Puma Biotechnology position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 930 Puma Biotechnology shares in Q4 2021, an estimated $6K.
  • Penserra Capital Management first reported a position in Puma Biotechnology in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's Puma Biotechnology position peaked at $9K in Q4 2020.
  • 102 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.